First Time Loading...

Haemonetics Corp
NYSE:HAE

Watchlist Manager
Haemonetics Corp Logo
Haemonetics Corp
NYSE:HAE
Watchlist
Price: 87.66 USD 1.67% Market Closed
Updated: Apr 27, 2024

Intrinsic Value

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. [ Read More ]

The intrinsic value of one HAE stock under the Base Case scenario is 87.28 USD. Compared to the current market price of 87.66 USD, Haemonetics Corp is Fairly Valued.

Key Points:
HAE Intrinsic Value
Base Case
87.28 USD
Fairly Valued
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Haemonetics Corp

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling HAE stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Haemonetics Corp

Provide an overview of the primary business activities
of Haemonetics Corp.

What unique competitive advantages
does Haemonetics Corp hold over its rivals?

What risks and challenges
does Haemonetics Corp face in the near future?

Has there been any significant insider trading activity
in Haemonetics Corp recently?

Summarize the latest earnings call
of Haemonetics Corp.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Haemonetics Corp.

Provide P/S
for Haemonetics Corp.

Provide P/E
for Haemonetics Corp.

Provide P/OCF
for Haemonetics Corp.

Provide P/FCFE
for Haemonetics Corp.

Provide P/B
for Haemonetics Corp.

Provide EV/S
for Haemonetics Corp.

Provide EV/GP
for Haemonetics Corp.

Provide EV/EBITDA
for Haemonetics Corp.

Provide EV/EBIT
for Haemonetics Corp.

Provide EV/OCF
for Haemonetics Corp.

Provide EV/FCFF
for Haemonetics Corp.

Provide EV/IC
for Haemonetics Corp.

Show me price targets
for Haemonetics Corp made by professional analysts.

What are the Revenue projections
for Haemonetics Corp?

How accurate were the past Revenue estimates
for Haemonetics Corp?

What are the Net Income projections
for Haemonetics Corp?

How accurate were the past Net Income estimates
for Haemonetics Corp?

What are the EPS projections
for Haemonetics Corp?

How accurate were the past EPS estimates
for Haemonetics Corp?

What are the EBIT projections
for Haemonetics Corp?

How accurate were the past EBIT estimates
for Haemonetics Corp?

Compare the revenue forecasts
for Haemonetics Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Haemonetics Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Haemonetics Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of Haemonetics Corp compared to its peers.

Compare the P/E ratios
of Haemonetics Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing Haemonetics Corp with its peers.

Analyze the financial leverage
of Haemonetics Corp compared to its main competitors.

Show all profitability ratios
for Haemonetics Corp.

Provide ROE
for Haemonetics Corp.

Provide ROA
for Haemonetics Corp.

Provide ROIC
for Haemonetics Corp.

Provide ROCE
for Haemonetics Corp.

Provide Gross Margin
for Haemonetics Corp.

Provide Operating Margin
for Haemonetics Corp.

Provide Net Margin
for Haemonetics Corp.

Provide FCF Margin
for Haemonetics Corp.

Show all solvency ratios
for Haemonetics Corp.

Provide D/E Ratio
for Haemonetics Corp.

Provide D/A Ratio
for Haemonetics Corp.

Provide Interest Coverage Ratio
for Haemonetics Corp.

Provide Altman Z-Score Ratio
for Haemonetics Corp.

Provide Quick Ratio
for Haemonetics Corp.

Provide Current Ratio
for Haemonetics Corp.

Provide Cash Ratio
for Haemonetics Corp.

What is the historical Revenue growth
over the last 5 years for Haemonetics Corp?

What is the historical Net Income growth
over the last 5 years for Haemonetics Corp?

What is the current Free Cash Flow
of Haemonetics Corp?

Discuss the annual earnings per share (EPS)
trend over the past five years for Haemonetics Corp.

Financials

Balance Sheet Decomposition
Haemonetics Corp

Current Assets 765m
Cash & Short-Term Investments 194m
Receivables 211.6m
Other Current Assets 359.4m
Non-Current Assets 1.4B
PP&E 318.7m
Intangibles 984.3m
Other Non-Current Assets 132.5m
Current Liabilities 261.8m
Accounts Payable 56.8m
Accrued Liabilities 58.8m
Other Current Liabilities 146.1m
Non-Current Liabilities 995.4m
Long-Term Debt 856.8m
Other Non-Current Liabilities 138.5m
Efficiency

Earnings Waterfall
Haemonetics Corp

Revenue
1.3B USD
Cost of Revenue
-590.8m USD
Gross Profit
679.3m USD
Operating Expenses
-480m USD
Operating Income
199.3m USD
Other Expenses
-72.8m USD
Net Income
126.5m USD

Free Cash Flow Analysis
Haemonetics Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

HAE Profitability Score
Profitability Due Diligence

Haemonetics Corp's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
57/100
Profitability
Score

Haemonetics Corp's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

HAE Solvency Score
Solvency Due Diligence

Haemonetics Corp's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
High Altman Z-Score
Long-Term Solvency
Low D/E
56/100
Solvency
Score

Haemonetics Corp's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

HAE Price Targets Summary
Haemonetics Corp

Wall Street analysts forecast HAE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HAE is 107.68 USD with a low forecast of 88.88 USD and a high forecast of 126 USD.

Lowest
Price Target
88.88 USD
1% Upside
Average
Price Target
107.68 USD
23% Upside
Highest
Price Target
126 USD
44% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

HAE Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

HAE Price
Haemonetics Corp

1M 1M
+4%
6M 6M
+4%
1Y 1Y
+6%
3Y 3Y
+31%
5Y 5Y
+0%
10Y 10Y
+181%
Annual Price Range
87.66
52w Low
71.24
52w High
93.49
Price Metrics
Average Annual Return 5.48%
Standard Deviation of Annual Returns 42.81%
Max Drawdown -69%
Shares Statistics
Market Capitalization 4.5B USD
Shares Outstanding 50 786 100
Percentage of Shares Shorted 6.1%

HAE Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Haemonetics Corp Logo
Haemonetics Corp

Country

United States of America

Industry

Health Care

Market Cap

4.5B USD

Dividend Yield

0%

Description

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. The company is headquartered in Boston, Massachusetts and currently employs 2,708 full-time employees. The firm provides a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. Its segments include Plasma, Blood Center and Hospital. Its Plasma segment offers automated plasma collection and donor management software systems that improve the donor experience at plasma collection centers. Its Blood Center segment offers a range of solutions that improve donor collection centers' ability to acquire blood, filter blood and separate blood components. Its Hospital segment provides the patient care. The company markets and sells its products to biopharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations and national health organizations.

Contact

MASSACHUSETTS
Boston
125 Summer Street
+17818487100.0
https://www.haemonetics.com

IPO

1979-10-17

Employees

2 708

Officers

CEO, President & Director
Mr. Christopher A. Simon
CFO, Executive VP & Financial Officer
Mr. James C. D'Arecca CPA
Executive VP & CTO
Ms. Anila Lingamneni
Executive VP, General Counsel & Secretary
Ms. Michelle L. Basil
Executive Vice President of Global Manufacturing & Supply Chain
Mr. Josep Lluis Llorens
VP, Chief Accounting Officer & Principal Accounting Officer
Ms. Farris Maryanne Maunsell
Show More
Senior Director of Investor Relations
Ms. Olga Guyette
Senior Vice President of Strategy & Corporate Development
Mr. Rajeev Varma
Senior VP & Chief Human Resources Officer
Ms. Laurie A. Miller
Senior VP & Chief Medical Officer
Dr. Jan Hartmann M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one HAE stock?

The intrinsic value of one HAE stock under the Base Case scenario is 87.28 USD.

Is HAE stock undervalued or overvalued?

Compared to the current market price of 87.66 USD, Haemonetics Corp is Fairly Valued.